ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / PCRX / options
TYRA (30) GHRS (49) ANAB (60) ETON (57) ⌘ Pro Terminal β†’

Pacira BioSciences Inc. (PCRX) Options Positioning, Max Pain & Unusual Sweeps

$36.40 +0.03% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $36.33

Pacira BioSciences Inc. (PCRX) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C β€’ HOLD / WATCH Cap $1.45B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PCRX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is PCRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Pacira BioSciences Inc. (NASDAQ: PCRX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $36.40 (+0.03% 1D, market cap $1.45B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, PCRX ranks #119 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does PCRX compare to TYRA and GHRS in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCRX carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of 79.4%, and ROIC of 1.7%. By comparison, TYRA (Tyra Biosciences Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $1.45B) and GHRS (GH Research PLC) posts a D grade (49/100 RQD, P/E N/A, ROIC β€”, cap $1.43B). Among the 5-stock peer group, PCRX leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PCRX?
β–Ό

Per PCRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001396814), Pacira BioSciences Inc. generated $726.4M in revenue (+3.6% YoY), $7.0M in net income, and $136.7M in free cash flow against $1.26B in total assets and $372.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $36.33 (-0.18%)🧬 Cannibal Buyback (-1.52% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 18.8% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY β€’ 55.6% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERHOLD / WATCH β€’ C
025507510065
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C Β· Rk B-
Cash (8)Whales (16)SEC (14)Macro (14)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+3.2% Base Target
$44 Bull$38 Base$29 Bear
πŸ“¬ FREE PCRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for PCRX)Realized 20D OHLCV Swing Band: Β±1.8%
Deterministic 5-Pillar Attribution (65/100 Composite)
πŸ” WHY PCRX SCORES 65/100 (C) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+16/20 pts (25% of score)

20D Institutional Volume Accumulation (Β±1.8% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (22% of score)

Altman Z-Score 2.33 (WATCH ZONE (1.8–3.0)) β€’ Piotroski F-Score 8/9

β–Ό #1 Drag / Risk Factor: Cash Engine Quality8/20 pts (-12 pt drag)

Capital intensity & 2.6% operating margin leave 12 pts on the table

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
57
Grade C$36.31+0.2% Next Q
Q2 (-2Q)
60
Grade C$36.38+0.1% Next Q
Q3 (-1Q)
62
Grade C+$36.40+0% Next Q
Current
65
Grade C$36.40+1.3% Hist 90D Ξ±
Trajectory: C (57) β†’ C (65)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the PCRX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 65/100 (C) score, PCRX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) β€” any gross margin slip below 76.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($29.53) or 200D SMA ($25.01) invalidates the momentum regime and cuts Target Base ($37.55) toward Bear Floor ($29.29).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PCRXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPCRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 65%NO 35%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±1.8%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PCRX)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PCRX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating PCRX & AI Leaders Without Chasing Tops

  • βœ“Institutional whale strikes & implied earnings move audit on PCRX
  • βœ“How disciplined traders manage risk using pre-published trigger & invalidation levels
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
PCRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.43%β–² ASCENDING CHANNEL
2026-11-03O $36.39H $36.40L $36.39C $36.40VOL 737.3K
RES: $38.20SUP: $23.95SMA50: $29.53SMA200: $25.01
$37.70$33.43$29.15$24.87$20.59RES $38.20SUP $23.95$36.402026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PCRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ PCRX Butterfly Map β†’ + Track PCRX β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
43.5%/yr Implied 5Y Growth

vs. +3.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PCRX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for PCRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PCRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PCRX)

Health Care Rank #119 of 1015 βš”οΈ TYRA vs PCRX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (PCRX vs. TYRA, GHRS, ANAB, ETON)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Pacira BioSciences Inc. (PCRX) ranks #119 by composite RQD confidence (65/100, grade C) and #304 by equity capitalization ($1.45B). Within this direct 5-issuer industry benchmark cohort, PCRX leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and β€” gross margin. PCRX currently leads its immediate peer cohort in composite quantitative strength at 65/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PCRX ACTIVE
Pacira BioSciences Inc.
C 65/100 β€” 79.4% 1.7% +0.03% $1.45B Benchmark Subject
TYRA
Tyra Biosciences Inc.
E 30/100 β€” β€” -35.0% +1.23% $1.45B /tyra-vs-pcrx β†’
GHRS
GH Research PLC
D 49/100 β€” β€” β€” -1.73% $1.43B /ghrs-vs-pcrx β†’
ANAB
AnaptysBio Inc.
C- 60/100 β€” β€” 85.0% -2.84% $1.43B /anab-vs-pcrx β†’
ETON
Eton Pharmaceuticals Inc.
D+ 57/100 β€” 53.5% -0.9% -2.63% $1.49B /eton-vs-pcrx β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001396814 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pacira BioSciences Inc. (PCRX) reported GAAP revenue of $726.4M (+3.6% vs. FY2024 revenue of $701.0M , and +7.6% cumulative change since FY2023) , GAAP net income of $7.0M, operating cash flow of $152.0M, and free cash flow of $136.7M (-23.5% YoY). On the balance sheet, PCRX closed FY2025 with $1.26B in total assets against $372.2M in total debt (Altman Z-Score: 2.33, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $726.4M $7.0M $152.0M $136.7M $1.26B $372.2M
FY2024 (FY) 2024-12-31 $701.0M -$99.6M $189.4M $178.8M $1.55B $383.5M
FY2023 (FY) 2023-12-31 $675.0M $42.0M $154.6M $154.6M β€” β€”

3. PCRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PCRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Pacira BioSciences Inc. (NASDAQ: PCRX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $36.40 (+0.03% 1D, market cap $1.45B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, PCRX ranks #119 in composite RQD confidence.

How does PCRX compare to TYRA and GHRS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCRX carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of 79.4%, and ROIC of 1.7%. By comparison, TYRA (Tyra Biosciences Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $1.45B) and GHRS (GH Research PLC) posts a D grade (49/100 RQD, P/E N/A, ROIC β€”, cap $1.43B). Among the 5-stock peer group, PCRX leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PCRX?

Per PCRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001396814), Pacira BioSciences Inc. generated $726.4M in revenue (+3.6% YoY), $7.0M in net income, and $136.7M in free cash flow against $1.26B in total assets and $372.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PCRX trading relative to its 50-day, 200-day, and 52-week technical levels?

PCRX last traded at $36.40 (+0.03% on volume of 810,961 shares), positioning the stock +23.26% above its 50-day simple moving average ($29.53) and +45.54% above its 200-day simple moving average ($25.01). Across its 52-week range of $18.80 to $36.67, PCRX sits at the 98.5% percentile with a 14-day RSI of 83.2 (OVERBOUGHT (>70)) and an implied next-earnings move of Β±1.8% ($35.74 to $37.06).

Direct Sub-Reports: PCRX RQD Cockpit PCRX 12M Forecast PCRX Earnings & Move PCRX Dividends & DRIP PCRX Insiders & 13F PCRX Whale Options PCRX Profit Sankey PCRX News & Why
ROARABLE RATING BRIEF β€’ RQD 65/100 (C) βœ“ SEC XBRL & RQD VERIFIED

PCRX β€” Pacira BioSciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Pacira BioSciences Inc. (PCRX) earns a live Roarable RQD composite score of 65/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $36.40 (+0.03% 1D, market capitalization $1.45B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of 1.7%, gross margin of 79.4%, operating margin of 2.6%, and free cash flow yield of 9.42%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.33, Piotroski F-Score of 8/9, and Debt/Equity of 0.54x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Pacira BioSciences Inc. (PCRX) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Per the recent news wire, Viatris has agreed to acquire Pacira, with the framing centered on non-opioid pain therapies.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Pacira BioSciences Inc. (PCRX) reported $726.4M in annual revenue (up from $701.0M in FY2024, +3.6% YoY) and $7.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($675.0M revenue, $42.0M net income) through FY2025, PCRX scaled operating cash flow to $152.0M and free cash flow to $136.7M, backed by $1.26B in total assets against $372.2M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (C β€’ RQD 65/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 9.42% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $18.80 – $36.67 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh current valuation and 51.6x EV/EBITDA against 2.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

An investor should note that the pending acquisition itself is the dominant event in the news flow; how it affects counterparties and sector peers is not resolved by the data.

  • Key Question #1: Can PCRX sustain or expand its 2.6% operating margin and 1.7% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $726.4M and free cash flow of $136.7M, how will capital allocation balance growth reinvestment against $372.2M in total debt?
  • Key Question #3: How sensitive is PCRX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PCRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pacira BioSciences Inc. (PCRX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to PCRX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PCRX Bull vs. Bear Conversation Board β€” What's Your Call at $36.40?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PCRX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PCRX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER β€’ Fundamental Long-Only πŸ‚ BULLISH 🎯 Target: $44.76 (+23.0%)
πŸ“Œ Pinned Debate

Institutional positioning (16/20 whale flow) and a Piotroski F-Score of 8/9 point to a financially sound, institutionally supported pro

The street is overcomplicating Pacira BioSciences Inc. (PCRX). Institutional positioning (16/20 whale flow) and a Piotroski F-Score of 8/9 point to a financially sound, institutionally supported profile amid a reported Viatris acquisition.. With an RQD score of 65/100 (C) and Forensic Balance Sheet at 14/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $39.30.

CapAlloc_Nerd πŸ‚ BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (79.4%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $28.38 (-22.0%)
Spot @ $36.39

ROIC of 1.7% and an EV/EBITDA of 51.6 leave weak capital efficiency and rich valuation against an operating margin of only 2.6%.

Sitting on the sidelines or leaning short PCRX above $36.39. ROIC of 1.7% and an EV/EBITDA of 51.6 leave weak capital efficiency and rich valuation against an operating margin of only 2.6%.. Until Fundamental Cash Engine (8/20) and FCF yield (9.42%) inflect higher, upside is capped near $36.67.

LIVE TAPE